Related Experiment Video
Updated: Aug 24, 2025

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
Programmed Aptamer Screening, Characterization, and Rapid Detection for α-Conotoxin MI
Han Guo1, Bowen Deng1, Luming Zhao1
1Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Naval Medical University, Shanghai 200433, China.
Abstract:
Conotoxins (CTXs) are a variety of mixed polypeptide toxins, among which α-conotoxin MI (CTX-MI) is the most toxic. Serious toxic symptoms, a lack of counteracting drugs, and cumbersome detection processes have made CTX-MI a hidden danger for humans. One of the obstacles to resolving this problem is the absence of specific recognition elements. Aptamers have shown great advantages in the fields of molecule detection, drug development, etc. In this study, we screened and characterized aptamers for CTX-MI through a programmed process. MBMI-01c, the isolated aptamer, showed great affinity, with an affinity constant (KD) of 0.524 μM, and it formed an antiparallel G-quadruplet (GQ) structure for the specific recognition of CTX-MI. Additionally, an aptasensor based on the biolayer interferometry (BLI) platform was developed and displayed high precision, specificity, and repeatability with a limit of detection (LOD) of 0.26 μM. This aptasensor provides a potential tool for the rapid detection of CTX-MI in 10 min. The aptamer can be further developed for the enrichment, detoxification, and biological studies of CTX-MI. Additionally, the programmed process is applicable to screening and characterizing aptamers for other CTXs.
Insights
Researchers developed a novel aptamer, MBMI-01c, for detecting the highly toxic α-conotoxin MI (CTX-MI). This aptamer enables rapid and specific CTX-MI detection, offering a potential tool for managing this dangerous toxin.
Area of Science:
- Biochemistry
- Molecular Biology
- Biotechnology
Background:
- α-conotoxin MI (CTX-MI) is a potent neurotoxin posing significant health risks due to its toxicity and lack of specific detection methods.
- The absence of specific recognition elements hinders the development of effective countermeasures and diagnostic tools for CTX-MI.
- Aptamers offer a promising alternative to traditional recognition elements, with demonstrated utility in molecular detection and drug development.
Purpose of the Study:
- To screen and characterize aptamers with high affinity and specificity for α-conotoxin MI (CTX-MI).
- To develop a sensitive and rapid aptasensor for CTX-MI detection.
- To establish a versatile aptamer screening methodology applicable to other conotoxins.
Main Methods:
- Programmed screening process to identify CTX-MI specific aptamers.
- Characterization of aptamer affinity using affinity constant (KD) measurements.
- Development of a biolayer interferometry (BLI) based aptasensor.
- Evaluation of aptasensor performance including precision, specificity, and limit of detection (LOD).
Main Results:
- An aptamer, MBMI-01c, was isolated with a high affinity (KD = 0.524 μM) for CTX-MI.
- MBMI-01c forms an antiparallel G-quadruplet (GQ) structure crucial for specific CTX-MI recognition.
- The developed BLI-based aptasensor demonstrated high precision, specificity, and repeatability with an LOD of 0.26 μM.
- The aptasensor achieved rapid CTX-MI detection within 10 minutes.
Conclusions:
- MBMI-01c is a highly effective aptamer for specific CTX-MI recognition.
- The developed aptasensor offers a precise, rapid, and repeatable method for CTX-MI detection.
- The aptamer holds potential for CTX-MI enrichment, detoxification, and biological studies.
- The aptamer screening methodology is adaptable for other conotoxins, expanding its utility.
More Related Videos
08:06Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays
Published on: November 10, 2016
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020